A case of Behçet disease with vitiligo, psoriasis and scleritis
More details
Hide details
Department of Rheumatology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Department of Ophthalmology, Municipal Hospital, Olsztyn, Poland
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2021-03-13
Final revision date: 2021-10-13
Acceptance date: 2021-10-13
Online publication date: 2021-11-16
Corresponding author
Grzegorz Chmielewski   

Department of Rheumatology, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Wojska Polskiego 30, 10-229 Olsztyn, Poland.
Pol. Ann. Med. 2022;29(2):211-215
Behçet disease (BD) is a rare systemic vasculitis of unknown aetiology, which can involve different size arteries and veins. The syndrome is characterized by oral aphthous ulcers, genital ulcers, skin and ocular lesions, arthritis, gastrointestinal ulcers, and neurological signs.

The aim of this paper is to discuss comorbidity of BD with other autoimmune diseases referring to a clinical case report.

Case study:
The study presents a case of BD concurrent with vitiligo, psoriasis and scleritis in a 22-year-old patient.

Results and discussion:
The aetiology and pathogenesis of BDare unknown. The presented case of BD was accompanied by psoriasis, nodular scleritis, and vitiligo, which is uncommon. In Poland, since the disease is rare and only single cases have been identified, the precise epidemiology is unknown. Currently, more cases are being diagnosed.

Due to nonspecific symptoms and rarity in some countries, BD diagnosis can be delayed, which may have a negative effect on a patient’s life quality. Further studies exploring the correlation between BD, psoriasis, vitiligo, and nodular scleritis are needed to better understand the pathogenesis and relationship between the diseases.

None declared.
None declared.
Kontogiannis V, Powell RJ. Behçet’s disease. Postgrad Med J. 2000;76(900):629–637.
Rokutanda R, Kishimoto M, Okada M. Update on the diagnosis and management of Behçet’s disease. Open Access Rheumatol. 2015;7:1–8.
Nair JR, Moots RJ. Behçet’s disease. Clin Med (Lond). 2017;17(1):71–77.
Davatchi F, Assaad-Khalil S, Calamia KT, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–347.
Woźniacka A, Sysa-Jędrzejowska A, Jurowski P, Jabłkowski M, Kot M. Morbus Behçet – a rare disease in Central Europe. Arch Med Sci. 2015;11(6):1189–1196.
Adeeb F, Stack AG, Fraser AD. Knitting the Threads of Silk through Time: Behçet’s Disease – Past, Present, and Future. Int J Rheumatol. 2017;2017:2160610.
Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7(1):4.
Wang Y, Li S, Li C. Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Med Sci Monit. 2019;25:1017–1023.
Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016;269(1):11–25.
Allam M, Riad H. Concise review of recent studies in vitiligo. Qatar Med J. 2013;23(2):1–19.
Ertaş R, Özyurt K, Avcı A, Ertas SK, Atasoy M. Case Report: Behçet’s disease accompanied with vitiligo. F1000Res. 2017;6:310.
Oran M, Hatemi G, Tasli L, et al. Behçet’s syndrome is not associated with vitiligo. Clin Exp Rheumatol. 2008;26(4 Suppl 50):107–109.
Borlu M, Çölgeçen E, Evereklioglu C. Behçet’s disease and vitiligo in two brothers: coincidence or association? Clin Exp Dermatol. 2009;34(8):653–655.
Cho S, Cho SB, Choi MJ, Zheng Z, Bang D. Behçet’s disease in concurrence with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(1):113–118.
Hahn HJ, Kwak SG, Kim DK, Kim JY. Association of Behçet disease with psoriasis and psoriatic arthritis. Sci Rep. 2021;11(1):2531.
Taylor J, Glenny AM, Walsh T, et al. Interventions for managing oral ulcers in Behçet's disease. Cochrane Database Syst Rev. 2014;9:CD011018.
Limtong P, Chanprapaph K, Vachiramon V, Ngamjanyap P. Cutaneous and Extracutaneous Manifestations of Behçet’s Disease Linked to Its Disease Activity and Prognosis. Clin Cosmet Investig Dermatol. 2020;13:639–647.
Senusi A, Seoudi N, Bergmeier LA, Fortun F. Genital ulcer severity score and genital health quality of life in Behçet’s disease. Orphanet J Rare Dis. 2015;10:117.
Rotondo C, Lopalco G, Iannone F, et al. Mucocutaneous Involvement in Behçet’s Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators Inflamm. 2015;2015:451675.
Scherrer MAR, Rocha VB, Garcia LC. Behçet´s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92(4):452–464.
Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–155.
Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50(4):297–350.
Tugal-Tutkun I. Behçet's Uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219–224.
Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M. HL-A5 and Behçet's disease. Lancet. 1973;2(7842):1383–1384.
de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA–B51/B5 and the Risk of Behçet’s Disease: A Systematic Review and Meta-Analysis of Case–Control Genetic Association Studies. Arthritis Rheum. 2009; 61(10):1286–1296.
Montes-Cano MA, Conde-Jaldón M, García-Lozano JR et al. HLA and non-HLA genes in Behçet’s disease: a multicentric study in the Spanish population. Arthritis Res Ther. 2013;15(5):R145.
Kirino Y, Nakajima H. Clinical and Genetic Aspects of Behçet’s Disease in Japan. Intern Med. 2019;58(9):1199–1207.
Journals System - logo
Scroll to top